Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Receives Grant from IWT

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Company has been awarded €2.4 million TGO grant for psoriasis research and development.

Galapagos NV has announced that it has been awarded a €2.4 million TGO (transformational medical research) grant from the Flemish agency for Innovation by Science and Technology (IWT) for psoriasis research and development.

The goal of this 4-year project is to bring a novel mode of action compound into the clinic that might lead to a safe and effective treatment for patients suffering from psoriasis.

Psoriasis is a common skin disease with a high impact on well-being and for which options for patient are currently limited.

Psoriasis is a chronic disease, affecting approximately 3% of the population. It has no final cure and therefore represents a high burden to quality of life.

Galapagos has discovered a compound series which presents a novel mode of action in psoriasis. This 4-year IWT funded research program will explore the potential application of this compound series in disease models for psoriasis, both in preclinical systems as well as in a clinical setting.

After the discovery phase, Galapagos will initiate clinical trials with this innovative, oral compound for psoriasis by using an adaptive trial design, with the aim of achieving an efficiency gain in development costs and timelines.

In the clinic, pharmacodynamic assessments will be evaluated in healthy volunteers by mimicking inflammation characteristics in a Proof-of-Mechanism study.

Galapagos will collaborate in this project with Professor Dr Jo Lambert at Ghent University.

"We are very pleased with this IWT grant, which really underscores how IWT supports innovation by biotechnology companies. This grant makes it possible to work towards a novel therapy which will hopefully improve the quality of life of psoriasis patients," said Piet Wigerinck, CSO of Galapagos.

Wigerinck continued, "Together with GSK2586184, in licensed by GlaxoSmithKline in 2012, we expect to have two drugs in development for psoriasis within two years."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Starts Phase 1 Study
Company has announced the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF).
Tuesday, May 10, 2016
Galapagos, Abbvie Expand Cystic Fibrosis Collaboration
Company has announced that it has expand cystic fibrosis collaboration with Abbvie to reflect the successful expansion of their CF portfolio.
Friday, April 29, 2016
Galapagos Reports Additional Data with Filgotinib
Company has reported 20-week results from its FITZROY study with the investigational, selective JAK1 inhibitor filgotinib in Crohn’s disease.
Saturday, April 23, 2016
Galapagos and MorphoSys initiate Phase 1 study
Company has initiated phase 1 study with MorphoSys AG in joint antibody program MOR106.
Friday, April 08, 2016
Galapagos Initiates a Phase 2a Study with GLPG1690
Company has announced that it has initiated a phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients.
Thursday, April 07, 2016
Galapagos Starts Saphira Phase 2 Study With Glpg1837 In Cystic Fibrosis Patients
Company has announced its Phase 2 exploratory program of GLPG1837 in patients with cystic fibrosis.
Wednesday, February 17, 2016
Galapagos and Gilead Complete Closing of their Global Collaboration for Filgotinib
Triggers an upfront license fee payment of $300 million and equity investment of $425 million.
Thursday, January 21, 2016
Galapagos Advances CF Clinical Development
Initiation of Phase 1 study with corrector GLPG2222, earning Galapagos a $10 million milestone payment from AbbVie.
Wednesday, January 20, 2016
Galapagos Advances Triple Combination Therapy in Cystic Fibrosis
GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy.
Wednesday, October 21, 2015
Positive Safety and Tolerability for Novel Potentiator GLPG1837
Company presents topline Phase 1 results at the North American Cystic Fibrosis Conference in Phoenix.
Saturday, October 10, 2015
Galapagos Presents Promising Pre-clinical and Phase 1 Results
Company presents results for autotaxin inhibitor GLPG1690 at ERS Annual Meeting.
Saturday, September 26, 2015
Galapagos to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis
Phase 3 start in RA expected in early 2016.
Saturday, September 26, 2015
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Tuesday, August 25, 2015
Patient Recruitment Completed in FITZROY Phase 2 Crohn's Disease Study
First selective JAK1 inhibitor in Phase 2 in Crohn's disease.
Friday, August 07, 2015
Galapagos Completes Recruitment for ORIGIN Phase 2 Trial
Recruitment for the Phase 2 Proof-of-Concept study with GPR84 inhibitor GLPG1205 in ulcerative colitis patients.
Saturday, June 20, 2015
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!